FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukaemia By Ogkologos - November 26, 2024 632 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASC4FIRST study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Using a Blood Test to Select Treatments for Advanced Gastrointestinal Stromal... January 23, 2023 A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in cHL August 25, 2020 Expecting Mom Finds Pregnant Stray Cat And Gives Her A Home July 30, 2021 EMA Recommends Extension of Indications for Cabozantinib July 10, 2025 Load more HOT NEWS Predicting future breast cancer with precision Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC Alabama’s Ventilator Rationing Plan Discriminates Against Disabled & Ill Patients, Advocacy...
